Fencamfamin: general
Fencamfamin (also spelled fencamfamine) is a prescription stimulant from the 1960s. The World Health Organization's drug-dependence committee described it as “a central nervous system stimulant with a pharmacological profile that resembles that of amphetamine”, and recorded that it had been prescribed as an energising drug since 1962 and “is marketed in 32 countries”.[1] Its chemical relative DiEt-fencamfamin, sold as a research chemical, has its own entry. This page is a summary of what is known and what is not. It is not medical advice and it gives no amounts.
How it acts
In laboratory tests on brain tissue, fencamfamin mainly blocked the recycling of dopamine rather than forcing its release, a profile its authors found “more similar to that of nomifensine” (a reuptake blocker) than to amphetamine.[2]
Dependence and abuse
The WHO committee reviewed fencamfamin in 1985 and found that “fencamfamin is self-administered by both beagle dogs and monkeys and it shows the typical pattern of a central stimulant reinforcer”.[1] In a study of dogs given the choice of fencamfamin or cocaine injections, the authors concluded: “It appears from these data that FEN may have a cocaine-like abuse potential”.[3] Rats taken off long-term fencamfamin became less active and gained weight, and the researchers wrote: “These results suggest that FCF caused signs of withdrawal similar to other psychostimulant drugs”.[4]
In people, the committee noted “there have been a few reports of social abuse by students” in some countries, and it recommended international control.[1] Fencamfamin has been in “Schedule IV of the 1971 Convention on Psychotropic Substances” since then.[1] The legal section covers what that means in the United States and elsewhere. We found no modern study of dependence in people: a PubMed search on 2026-11-21 returned 71 records, most of them animal and laboratory work from the 1980s and 1990s.[5] That is the limit of what our search found, not evidence that dependence does not happen. The animal results above point the other way.
What the human studies found
There are human data, but they are old and small. A Brazilian study gave fencamfamin to “six healthy male volunteers” and found that rises in “heart rate, blood pressure and stimulation assessed by self-rating, were more pronounced with the higher dose of fencamfamine”.[6] At the lower amount some volunteers had “Paradoxical sedative effects” instead.[6] A British trial compared it with dexamphetamine and mazindol in “Twenty patients with the narcoleptic syndrome”, and found that “Effects on mood, alertness, and sympathomimetic side effects were largely inseparable with all these drugs”.[7] In other words, in that trial it behaved like a conventional stimulant, side effects included.
None of these studies tested long-term use, mixing with other drugs, or products bought outside a pharmacy. There is no established safe amount for use without a prescription.
Heart and overdose risks of the class
No case series of fencamfamin overdose turned up in our search, so what follows is what the US Centers for Disease Control and Prevention says about stimulants in general, and fencamfamin raised heart rate and blood pressure in the volunteer study above.[6][5] The CDC notes that “not all stimulant overdoses look the same”, and that “it is hard to know how much is 'too much' or harmful for any given person”.[8] Among the signs that need medical attention it lists a fast or irregular heartbeat, overheating, high blood pressure and “chest pains or tightness”.[8] Those risks are higher for anyone with heart disease or high blood pressure, and when stimulants are combined.
What is not known
How fencamfamin interacts with other drugs has not been studied in people, as far as our search found; that includes antidepressants, other stimulants and alcohol.[5] What it does over months of use, and whether a powder sold under its name contains it at all, is unknown.
References
- Fencamfamin: ECDD technical summary and recommendation (22nd Expert Committee on Drug Dependence, 1985) — World Health Organization, Expert Committee on Drug Dependence information repository
- Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study (Biochemical Pharmacology, 1983) — PubMed (US National Library of Medicine)
- Intravenous self-administration of fencamfamine and cocaine by beagle dogs under fixed-ratio and progressive-ratio schedules of reinforcement (Risner and Cone, Drug and Alcohol Dependence, 1986) — PubMed (US National Library of Medicine)
- Effects of fencamfamine withdrawal in rats (Planeta, DeLucia and Aizenstein, General Pharmacology, 1994) — PubMed (US National Library of Medicine)
- PubMed search for fencamfamin OR fencamfamine OR reactivan (run 2026-11-21: 71 records, mostly rat and in vitro work from the 1980s and 1990s, a few small human studies) — PubMed (US National Library of Medicine)
- Psychostimulant effects of fencamfamine in healthy volunteers (Gorenstein, DeLucia and Gentil, Brazilian Journal of Medical and Biological Research, 1988) — PubMed (US National Library of Medicine)
- Amphetamine, mazindol, and fencamfamin in narcolepsy (Shindler et al., British Medical Journal, 1985) — PubMed (US National Library of Medicine)
- Stimulant Guide: Overdose Prevention and Response (2024) — US Centers for Disease Control and Prevention
Comments
Sign in to join the conversation.
No comments yet.